IP Library Granted Patent US 9,902,951
Granted Patent B2
US 9,902,951 · App. 13/886,234 · Granted Feb 27, 2018

Method of nucleic acid amplification

Inventors: Eric H. Kawashima (Pacific Grove, CA); Laurent Farinelli (Plan-les-Ouates, CH); Pascal Mayer (Saint-Beauzire, FR)
Assignees: Illumina, Inc.; Illumina Cambridge Limited
C12N15/1065C12Q1/686C12Q1/6834C12Q1/6837C12Q1/6853C12Q1/6869C12Q1/6874
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,951
App. No.
13/886,234
Granted
Feb 27, 2018
Kind
B2
Abstract

A nucleic acid molecule can be annealed to an appropriate immobilized primer. The primer can then be extended and the molecule and the primer can be separated from one another. The extended primer can then be annealed to another immobilized primer and the other primer can be extended. Both extended primers can then be separated from one another and can be used to provide further extended primers. The process can be repeated to provide amplified, immobilized nucleic acid molecules. These can be used for many different purposes, including sequencing, screening, diagnosis, in situ nucleic acid synthesis, monitoring gene expression, nucleic acid fingerprinting, etc.

Claims (34)

1. A process that can be used to identify in a nucleic acid sample the presence or absence of nucleic acid sequence differences, wherein each said difference is with respect to one or more reference sequences, the process comprising:

a) fragmenting nucleic acids in said sample;

b) linking adapter sequences to the nucleic acid fragments generated in step a);

c) binding said nucleic acid fragments to a solid support to form bound nucleic acid fragments, and amplifying said bound nucleic acid fragments; and

d) identifying nucleic acid sequences within said amplified nucleic acid fragments.

2. The process of claim 1 wherein there are a plurality of solid supports which each immobilizes primers which bind said nucleic acid fragments to the solid supports.

3. The process of claim 2 wherein the primers effect separation by interacting with or hybridizing to the adapter sequences.

4. The process of claim 2 wherein the solid supports are beads or a nylon or nitrocellulose membrane having an oligonucleotide capable of hybridizing to the adapter sequences attached to the nucleic acid fragments.

5. The process of claim 1 wherein sequence differences are identified in at least 10,000 nucleic acid fragments.

6. The process of claim 1 wherein the fragmenting is with restriction enzyme digestion.

7. The process of claim 1 wherein the nucleic acid fragments are amplified before or after step b of claim 2 .

8. The process of claim 1 wherein the identifying of nucleic acid sequences in step (d) includes hybridizing sequencing primers to the amplified nucleic acid fragments.

9. The process of claim 8 wherein the sequencing primers are extended following hybridization.

10. The process of claim 1 wherein the adapter sequences are operatively linked to the nucleic acid fragments in step (b).

11. The process of claim 1 wherein the adapter sequences are ligated to the nucleic acid fragments in step (b).

12. The process of claim 9 wherein the sequencing primers are extended using a DNA polymerase.

13. The process of claim 1 wherein the identifying of nucleic acid sequences in step (d) includes monitoring the sequential addition of nucleotides to a primer.

14. The process of claim 1 wherein sequence differences are identified in over 1,000 nucleic acid fragments or over 1,000,000 nucleic acid fragments.

15. A process to identify in a nucleic acid sample the presence or absence of a nucleic add sequence difference with respect to a reference sequence, the process comprising:

a) fragmenting nucleic acids in said sample;

b) linking adapter sequences to the nucleic acid fragments generated in step a);

c) binding said nucleic acid fragments to a solid support by hybridizing the adapter sequences to complementary oligonucleotides attached to said solid support to form bound nucleic acid fragments, and amplifying said bound nucleic acid fragments to produce bound and amplified fragments, whereby there is enrichment of subsets of the nucleic acid fragments; and

d) identifying the presence or absence of nucleic acid sequence differences within said bound and amplified fragments with respect to the reference sequence by hybridizing sequencing primers to the bound and amplified fragments and extending the sequencing primers.

16. The process of claim 15 wherein said complementary oligonucleotides act as primers in amplifying said solid support bound nucleic acid fragments.

17. The process of claim 15 wherein there are a plurality of solid supports which each immobilizes primers.

18. The process of claim 17 wherein the primers are oligonucleotides which bind the nucleic acid fragments to the solid support by hybridizing to the adapter sequences.

19. The process of claim 15 wherein the solid support is beads or a nylon or nitrocellulose membrane.

20. The process of claim 15 wherein the enrichment is of subsets such that the nucleic acid fragments in the subsets have particular lengths.

21. The process of claim 15 wherein sequence differences are identified in at least 10,000 nucleic acid fragments.

22. The process of claim 15 wherein the fragmenting is with restriction enzyme digestion.

23. The process of claim 15 wherein the nucleic acid fragments are amplified before or after step b).

24. The process of claim 15 wherein the adapter sequences are ligated to the nucleic acid fragments in step b).

25. The process of claim 15 wherein the adapter sequences are operatively linked to the nucleic acid fragments in step b).

26. The process of claim 22 wherein the nucleic acid fragments are size-fractionated.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2014
From: GLAXO GROUP LIMITED
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 032868/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2014
From: KAWASHIMA, ERIC H.; FARINELLI, LAURENT; MAYER, PASCAL
To: GLAXO GROUP LIMITED
Reel/Frame 032874/0519 →
CHANGE OF NAME Recorded May 9, 2014
From: SOLEXA LIMITED
To: ILLUMINA CAMBRIDGE LIMITED
Reel/Frame 032864/0209 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2014
From: SMITHKLINE BEECHAM CORPORATION
To: MANTEIA SA
Reel/Frame 032864/0123 →
CHANGE OF NAME Recorded May 9, 2014
From: LYNX THERAPEUTICS INC.
To: SOLEXA, INC.
Reel/Frame 032864/0753 →
MERGER Recorded May 9, 2014
From: SOLEXA, INC.
To: ILLUMINA, INC.
Reel/Frame 032864/0218 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2014
From: MANTEIA SA
To: SOLEXA LTD.; LYNX THERAPEUTICS INC.
Reel/Frame 032864/0148 →
Priority Claims (4)
GB 9706528.8 · Apr 1, 1997 · national
GB 9706529.6 · Apr 1, 1997 · national
GB 9713236.9 · Jun 23, 1997 · national
GB 9713238.5 · Jun 23, 1997 · national
Continuity (5)
Continuation 13828047 · Mar 14, 2013
Continuation 12148133 · Apr 16, 2008
Division 10449010 · Jun 2, 2003
Continuation 09402277
Related Publication 20130231254A1 · Sep 5, 2013